000 03581nam a22004455i 4500
001 978-1-4419-5635-4
003 DE-He213
005 20140220084507.0
007 cr nn 008mamaa
008 100825s2010 xxu| s |||| 0|eng d
020 _a9781441956354
_9978-1-4419-5635-4
024 7 _a10.1007/978-1-4419-5635-4
_2doi
050 4 _aRE1-994
072 7 _aMJQ
_2bicssc
072 7 _aMED063000
_2bisacsh
082 0 4 _a617.7
_223
100 1 _aLambris, John D.
_eeditor.
245 1 0 _aInflammation and Retinal Disease: Complement Biology and Pathology
_h[electronic resource] /
_cedited by John D. Lambris, Anthony P. Adamis.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2010.
300 _aXIV, 170 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v703
505 0 _aThe Case for Complement and Inflammation in AMD: Open Questions -- The Role of Complement in AMD -- Multiple Interactions of Complement Factor H with Its Ligands in Solution: A Progress Report -- Genetic Control of Complement Activation in Humans and Age Related Macular Degeneration -- Bisretinoids of RPE Lipofuscin: Trigger for Complement Activation in Age-Related Macular Degeneration -- The Role of the Classical Complement Cascade in Synapse Loss During Development and Glaucoma -- A Role for Complement in Glaucoma? -- The ATP-Binding Cassette Transporter ABCA4: Structural and Functional Properties and Role in Retinal Disease -- Suppression of Drusen Formation by Compstatin, a Peptide Inhibitor of Complement C3 activation, on Cynomolgus Monkey with Early-Onset Macular Degeneration -- A Targeted Inhibitor of the Complement Alternative Pathway Reduces RPE Injury and Angiogenesis in Models of Age-Related Macular Degeneration -- Complement Depletion with Humanized Cobra Venom Factor in a Mouse Model of Age-Related Macular Degeneration.
520 _aNumerous studies have pointed to the key role of complement in the pathogenesis of retinal disease, particularly age-related macular degeneration (AMD). Reports about new gene associations and links to other physiological pathways are emerging almost on a weekly base. Several promising clinical candidates covering a wide area of potential treatment applications are in the pipelines of both industrial and academic groups. This indicates an increasing interest in complement as a therapeutic target. In view of these exciting discoveries, scientists from around the world convened at the 1st Aegean Conferences Conference on Inflammation and Retinal Disease: Complement Biology and Pathology (June 10-17, 2007) in Crete, Greece, to discuss recent advances in this rapidly-evolving field. This volume represents a collection of topics on the functions of complement in eye diseases, pathophysiology, protein structures, and complement therapeutics discussed during the conference.
650 0 _aMedicine.
650 0 _aOphthalmology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOphthalmology.
700 1 _aAdamis, Anthony P.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781441956347
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v703
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4419-5635-4
912 _aZDB-2-SBL
999 _c110493
_d110493